Strategic merger Nova Biomedical's consolidation with Advanced Instruments creates a larger global life science tools player, signaling opportunities to cross-sell integrated bioprocessing, clinical diagnostics, and veterinary solutions to a broader customer base.

Expanded product scope The combined portfolio enhances capabilities in bioprocessing, cell line development, real-time cell culture monitoring, and IVD, enabling targeted upsell around end-to-end workflows for labs seeking single-vendor efficiency.

Global reach With operations in over 100 countries and status as a leading privately held IVD company, there is potential to pursue multinational accounts and capture demand from institutions seeking reliable, scalable instruments and support.

Innovation pipeline Ongoing reinvestment in R&D supports a strong pipeline of technology advances (glycan screening, automated osmometers, clonal cell imaging) that sales teams can leverage to present differentiating future-ready solutions.

Integration opportunities Existing tech stack and recent product launches indicate room to bundle hardware, software, and services (supply chain, data management, automation) into comprehensive solutions for clinical labs and biopharma manufacturing.